Media & Press Updates
What’s Happening
November 7, 2017
KINGSTON, R.I, November 07, 2017 — Experts at the University of Rhode Island have been named partners in all three of the latest Innovation Vouchers awarded by the Rhode Island Commerce Corp. And in one case, the small business partnering with the University is led by URI graduate students... continue reading
URI sweeps latest round of state Innovation Voucher grants
October 13, 2017
Fed up with the “status quo” in the pharmaceutical industry and inspired by the “endless possibilities” in drug development, current University of Rhode Island College of Pharmacy Ph.D. students Kenneth Rose, Nicholas DaSilva and Benjamin Barlock launched Alcinous Pharmaceuticals last December. The human body “is one giant puzzle,” said Rose of the URI-based company’s challenge.… continue reading
Campus business in drug research
June 9, 2017
Anyone who has known a cancer patient knows that treatments can be difficult. Three PhD students at URI are trying to help. They're working to develop potential new medications. They’re grad students by day and executives by night... continue reading
URI Students Launch Pharmaceutical Company
June 6, 2017
Three Ph.D. students at the University of Rhode Island’s College of Pharmacy have started a company that harnesses big data in a novel approach to drug development... continue reading
URI graduate students launch pharmaceutical company
We always have a story to tell, to check our news section often and contact us if you need more information!
We’re happy to hear from you. Contact us today to learn more about our business.
Contact
Email:
Phone:
401-433-9603
Meet The Team
Who We Are
Nicholas DaSilva
Chief Executive Officer
Kenneth N. Rose
Chief Scientific Officer
Benjamin Barlock
Chief Technology Officer
David Worthen
Chief Operations Officer
PARP Inhibitors
Poly ADP-Ribose Polymerase inhibitors are a rapidly expanding class of oncology drugs. PARP inhibitors currently in clinical use have been granted breakthrough status by the FDA. Here at Alcinous, we have designed new classes of PARP inhibitors in an effort to reduce their toxicity, increase their effectiveness and patient tolerability, and improve patient outcomes.
Our Technology
Novel Interactions with Therapeutic Targets
At Alcinous Pharmaceuticals, we design and develop new molecules that modulate the activity of well-established protein targets related to oncology and other pathologies. Our computational and synthetic approaches facilitate the identification and development of novel target ligands and new therapeutics.
Who We Are
Innovators
We strive to design and develop therapeutics for aggressive cancers. Founded in 2016 by three PhD students at the University of Rhode Island, Alcinous Pharmaceuticals uses a novel drug discovery pipeline in tandem with their innovative team to develop new classes of therapeutics.
Welcome to Alcinous Pharmaceuticals
Alcinous strives to produce innovative therapies for a variety of oncology purposes using a computational approach.
